Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.

adipokine breast cancer cinnamaldehyde visfatin

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
06 Dec 2019
Historique:
received: 04 11 2019
revised: 25 11 2019
accepted: 05 12 2019
entrez: 11 12 2019
pubmed: 11 12 2019
medline: 11 12 2019
Statut: epublish

Résumé

Excessive growth of cancer cells is the main cause of cancer mortality. Therefore, discovering how to inhibit cancer growth is an important research topic. Recently, the newly discovered adipokine, known as nicotinamide phosphoribosyl transferase (NAMPT, visfatin), which has been associated with metabolic syndrome and obesity, has also been found to be a major cause of cancer proliferation. Therefore, inhibition of NAMPT and reduction of Nicotinamide adenine dinucleotide (NAD) synthesis is one strategy for cancer therapy. Cinnamaldehyde (CA), as an antioxidant and anticancer natural compound, may have the ability to inhibit visfatin. The breast cancer cell line and xenograft animal models were treated under different dosages of visfatin combined with CA and FK866 (a visfatin inhibitor) to test for cell toxicity, as well as inhibition of tumor-related proliferation of protein expression. In the breast cancer cell and the xenograft animal model, visfatin significantly increased proliferation-related protein expression, but combination with CA or FK866 significantly reduced visfatin-induced carcinogenic effects. For the first time, a natural compound inhibiting extracellular and intracellular NAMPT has been demonstrated. We hope that, in the future, this can be used as a potential anticancer compound and provide further directions for research.

Identifiants

pubmed: 31817697
pii: antiox8120625
doi: 10.3390/antiox8120625
pmc: PMC6943554
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Cell Physiol. 2019 Apr;234(4):5011-5022
pubmed: 30471099
PLoS One. 2014 Sep 30;9(9):e107315
pubmed: 25268975
Int J Mol Sci. 2017 Sep 21;18(10):null
pubmed: 28934130
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Pharmacol Res. 2016 Dec;114:274-283
pubmed: 27816507
Eur J Cancer Prev. 2015 May;24(3):231-9
pubmed: 25055182
Annu Rev Nutr. 2010 Aug 21;30:173-99
pubmed: 20420526
Obes Res Clin Pract. 2016 Jul-Aug;10(4):442-53
pubmed: 26388139
Biochem Biophys Res Commun. 2017 Nov 25;493(3):1260-1266
pubmed: 28958934
BMC Cancer. 2010 May 18;10:210
pubmed: 20482751
Compr Physiol. 2017 Mar 16;7(2):603-621
pubmed: 28333382
Endocrinology. 2012 Feb;153(2):554-63
pubmed: 22186408
Cell Physiol Biochem. 2019;52(6):1398-1411
pubmed: 31075190
J Biol Chem. 2015 Nov 6;290(45):27124-37
pubmed: 26385918
Clin Cancer Res. 2016 Sep 1;22(17):4478-90
pubmed: 27036136
Med Hypotheses. 2012 Nov;79(5):617-21
pubmed: 22922056
Sci Pharm. 2015 Sep 26;84(1):41-59
pubmed: 27110497
Prog Mol Biol Transl Sci. 2017;151:1-32
pubmed: 29096890
J Pharm Biomed Anal. 2014 Feb;89:150-7
pubmed: 24291110
Peptides. 2014 Jan;51:86-90
pubmed: 24269296
J Cell Physiol. 2019 Apr;234(4):5289-5303
pubmed: 30317581
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Phytother Res. 2016 May;30(5):754-67
pubmed: 26890810
Int J Cancer. 2018 Sep 1;143(5):1037-1046
pubmed: 29569713
Int J Mol Sci. 2018 Nov 19;19(11):null
pubmed: 30463229
Int J Biochem Cell Biol. 2017 Mar;84:58-74
pubmed: 28093328
Cancer Biol Ther. 2010 Jul 15;10(2):119-25
pubmed: 20647743
Gynecol Oncol. 2016 Oct;143(1):168-178
pubmed: 27473926
Science. 2015 Dec 4;350(6265):1208-13
pubmed: 26785480
Pharmacol Res. 2017 Aug;122:78-89
pubmed: 28559210
Peptides. 2017 Jun;92:9-15
pubmed: 28442350
Science. 2005 Jan 21;307(5708):366-7
pubmed: 15604359
Endocr J. 2017 Apr 29;64(4):393-401
pubmed: 28190851
Obesity (Silver Spring). 2008 Nov;16(11):2552-5
pubmed: 18719677

Auteurs

Yi-Fen Chiang (YF)

Graduate Institute of Metabolism and Obesity Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.
School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.

Hsin-Yuan Chen (HY)

School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.

Ko-Chieh Huang (KC)

School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.

Po-Han Lin (PH)

School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.

Shih-Min Hsia (SM)

Graduate Institute of Metabolism and Obesity Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.
School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.
School of Food and Safety, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.
Nutrition Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan.

Classifications MeSH